Burning Rock Biotech (BNR) Earnings Analysis

Burning Rock Biotech (BNR) next reports earnings on 2026-09-02, consensus EPS -2.30601 USD. Last quarter (2026-06-09) it beat with EPS -0.2 USD vs -2.28836 USD est (+91.3%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E -1.10.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BNR next report earnings?

Next earnings date2026-09-02
Consensus EPS estimate-2.30601 USD
Revenue estimate0.02B

BNR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-06-09-0.2 USD-2.28836 USD+91.3%Beat
2026-03-12-0.21 USD-1.39699 USD+85%Beat
2025-11-20-0.26 USDn/an/an/a
2025-09-08-0.15 USDn/an/an/a
2025-06-06-0.17 USDn/an/an/a
2024-12-03-0.5 USD-1.41035 USD+64.5%Beat
2024-08-22-0.14 USD-1.48565 USD+90.6%Beat

Beat rate: 4/4 (100%) over reported quarters with consensus data.

BNR valuation and analyst view

Trailing P/E-1.10
Trailing EPS-56.38815 USD
Price / book0.13
Dividend yield0.00%
Market cap0.01B
Analyst consensusBuy (3 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is Burning Rock Biotech (BNR)'s next earnings date?

Burning Rock Biotech is next scheduled to report on 2026-09-02, with a consensus EPS estimate of -2.30601 USD and revenue estimate of 0.02B.

Did BNR beat earnings last quarter?

In its 2026-06-09 report, BNR posted EPS of -0.2 USD versus a -2.28836 USD estimate — a beat of 91.3%.

What is BNR's earnings track record?

Over the last 4 reported quarters with consensus data, BNR beat estimates 4 times (100%).

What is BNR's current P/E ratio and EPS?

BNR trades at a trailing P/E of -1.10 on trailing EPS of -56.388145276045535 USD.

What do analysts rate BNR?

Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell).